DE69034040T2 - Rekombinanter Abkömmling des menschlichen Faktors VIII - Google Patents

Rekombinanter Abkömmling des menschlichen Faktors VIII

Info

Publication number
DE69034040T2
DE69034040T2 DE69034040T DE69034040T DE69034040T2 DE 69034040 T2 DE69034040 T2 DE 69034040T2 DE 69034040 T DE69034040 T DE 69034040T DE 69034040 T DE69034040 T DE 69034040T DE 69034040 T2 DE69034040 T2 DE 69034040T2
Authority
DE
Germany
Prior art keywords
factor viii
human factor
recombinant
dna segment
descendant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69034040T
Other languages
English (en)
Other versions
DE69034040D1 (de
Inventor
Anneli B Almstedt
Eva Maria Hellstroem
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Mona Sydow-Baeckman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69034040(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum AB filed Critical Biovitrum AB
Application granted granted Critical
Publication of DE69034040D1 publication Critical patent/DE69034040D1/de
Publication of DE69034040T2 publication Critical patent/DE69034040T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)
DE69034040T 1989-12-15 1990-12-06 Rekombinanter Abkömmling des menschlichen Faktors VIII Expired - Lifetime DE69034040T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (sv) 1989-12-15 1989-12-15 Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

Publications (2)

Publication Number Publication Date
DE69034040D1 DE69034040D1 (de) 2003-03-13
DE69034040T2 true DE69034040T2 (de) 2003-11-20

Family

ID=20377785

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69034040T Expired - Lifetime DE69034040T2 (de) 1989-12-15 1990-12-06 Rekombinanter Abkömmling des menschlichen Faktors VIII
DE1999175066 Active DE19975066I2 (de) 1989-12-15 1990-12-06 Rekombinanter Abk¦mmling des menschlichen Faktors III.
DE69032600T Expired - Lifetime DE69032600T3 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE1999175066 Active DE19975066I2 (de) 1989-12-15 1990-12-06 Rekombinanter Abk¦mmling des menschlichen Faktors III.
DE69032600T Expired - Lifetime DE69032600T3 (de) 1989-12-15 1990-12-06 Rekombinanter abkömmling des menschlichen faktors iii

Country Status (21)

Country Link
EP (3) EP0506757B2 (de)
JP (1) JP2644084B2 (de)
AT (2) ATE232213T1 (de)
AU (1) AU645539B2 (de)
BR (1) BR9007921A (de)
CA (1) CA2071875C (de)
DE (3) DE69034040T2 (de)
DK (2) DK0506757T4 (de)
ES (2) ES2189897T3 (de)
FI (1) FI104260B1 (de)
HK (2) HK1009290A1 (de)
HU (1) HU211504A9 (de)
IE (1) IE904510A1 (de)
LU (1) LU90457I2 (de)
NL (1) NL990035I2 (de)
NO (1) NO309041B1 (de)
NZ (1) NZ236276A (de)
PT (1) PT96208B (de)
SE (1) SE465222C5 (de)
SG (1) SG66753A1 (de)
WO (1) WO1991009122A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
SE9300509D0 (sv) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab Peg treatment
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1318198B1 (de) * 1996-05-14 2006-03-22 Biovitrum Ab Verfahren zur Herstellung eines rekombinanten Polypeptids unter Hinzufügung eines Chymotrypsinhemmstoffes zum Zellkulturmedium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
CA2404163C (en) * 2000-03-22 2009-09-29 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
JP2005532057A (ja) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
EP1596887B1 (de) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii-konjugate
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP2298926A1 (de) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Claden (Subtypen) und Sequenzen von Adeno-Assoziiertem Virus (AAV), diese enthaltende Vektoren und ihre Verwendungen
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP2371856B1 (de) 2004-11-12 2022-05-18 Bayer HealthCare LLC Ortsgerichtete Modifizierung von FVIII
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP3409296A1 (de) 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2522717B1 (de) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptid-freie Zellkulturmedien
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2101821B1 (de) 2006-12-15 2014-08-13 Baxter International Inc. Faktor-viia-(poly)sialsäurekonjugat mit verlängerter in-vivo-halbwertszeit
KR101389376B1 (ko) 2007-02-23 2014-04-29 에스케이케미칼주식회사 제 ８ 인자 및 그의 유도체의 제조 및 정제 방법
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
DK2235197T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
EP2393828B1 (de) 2009-02-03 2016-10-12 Amunix Operating Inc. Verlängerte rekombinante polypeptide und zusammensetzungen damit
NO2440239T3 (de) 2009-06-09 2018-02-10
EP2459224B1 (de) 2009-07-27 2016-06-01 Baxalta GmbH Koagulationsproteinkonjugate
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
EP4382170A2 (de) 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zur verwendung davon
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
EP3508573A1 (de) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systeme für faktor viii-verarbeitung und verfahren davon
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103209992A (zh) * 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PL2675902T3 (pl) 2011-02-17 2019-08-30 The Trustees Of The University Of Pennsylvania Kompozycje i sposoby do zmieniania specyficzności względem tkanki i poprawy transferu genu z udziałem aav9
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
AR087091A1 (es) 2011-07-08 2014-02-12 Biogen Idec Hemophilia Inc Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
LT2804623T (lt) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
LT2882450T (lt) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas
RU2500818C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАР227, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 2H5 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА VIII СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ ФАКТОРА VIII
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (de) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
RS61387B1 (sr) 2013-02-15 2021-02-26 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
EP2968498A4 (de) 2013-03-15 2016-09-07 Biogen Ma Inc Faktor-ix-polypeptidformulierungen
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3013358A4 (de) 2013-06-28 2017-03-22 Biogen MA Inc. Durch thrombin spaltbarer linker mit xten und verwendungen davon
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
MX2016005333A (es) 2013-10-22 2017-02-15 Dbv Tech Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US9771403B2 (en) 2013-12-09 2017-09-26 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
CN116731201A (zh) 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
EP3331608A4 (de) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. Faktor-ix-fusionsproteine und verfahren zur herstellung und verwendung davon
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
MA46968A (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc Procédés d'induction de tolérance immunitaire à des facteurs de coagulation
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3665289A1 (de) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nukleinsäuremoleküle und verwendungen davon
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
UY38160A (es) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc Partículas implantables y métodos relacionados
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
MX2021015897A (es) 2019-06-19 2022-04-18 Bioverativ Therapeutics Inc Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
US20240043494A1 (en) 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same
KR20240049332A (ko) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. 최적화된 인자 viii 유전자
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (de) * 1986-01-03 1993-03-31 Genetics Institute, Inc. Verfahren zur herstellung von faktor-viii:c-typ-proteinen
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
JPH0637425B2 (ja) * 1986-11-11 1994-05-18 株式会社クラレ 高沸点（メタ）アクリル酸エステルの製造方法
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JP2586092B2 (ja) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 多官能（メタ）アクリル酸エステルの製造法
DK0500734T3 (da) * 1989-11-17 1998-03-30 Chiron Corp Proteinkomplekser med faktor VIII:C-aktivitet samt frembringelse deraf

Also Published As

Publication number Publication date
EP0506757B2 (de) 2005-10-26
HK1009290A1 (en) 1999-05-28
SE465222C5 (sv) 1998-02-10
DK0506757T3 (da) 1999-05-25
DE69032600T3 (de) 2006-07-20
EP1293513A3 (de) 2003-04-02
BR9007921A (pt) 1992-11-10
AU7039391A (en) 1991-07-18
NL990035I2 (nl) 2000-01-03
HU211504A9 (en) 1995-11-28
ES2189897T3 (es) 2003-07-16
SE465222B (sv) 1991-08-12
WO1991009122A1 (en) 1991-06-27
SE8904239D0 (sv) 1989-12-15
NO922325D0 (no) 1992-06-12
DK0506757T4 (da) 2006-02-20
DK0786474T3 (da) 2003-03-03
CA2071875C (en) 2006-08-08
AU645539B2 (en) 1994-01-20
EP0786474B1 (de) 2003-02-05
CA2071875A1 (en) 1991-06-16
SG66753A1 (en) 2001-12-19
FI104260B (fi) 1999-12-15
EP1293513A2 (de) 2003-03-19
DE69032600T2 (de) 1999-01-07
DE69034040D1 (de) 2003-03-13
ES2119769T5 (es) 2006-04-16
ATE232213T1 (de) 2003-02-15
PT96208B (pt) 1998-05-29
EP0786474A1 (de) 1997-07-30
JPH05502161A (ja) 1993-04-22
NZ236276A (en) 1993-03-26
DE19975066I2 (de) 2005-07-07
FI922745A0 (fi) 1992-06-12
NL990035I1 (nl) 1999-12-01
IE904510A1 (en) 1991-07-17
SE8904239L (sv) 1991-06-16
ES2119769T3 (es) 1998-10-16
NO309041B1 (no) 2000-12-04
PT96208A (pt) 1991-09-30
JP2644084B2 (ja) 1997-08-25
EP0506757A1 (de) 1992-10-07
LU90457I2 (fr) 2001-04-13
HK1019449A1 (en) 2000-02-11
FI104260B1 (fi) 1999-12-15
NO922325L (no) 1992-08-11
ATE170219T1 (de) 1998-09-15
EP0506757B1 (de) 1998-08-26
DE69032600D1 (de) 1998-10-01

Similar Documents

Publication Publication Date Title
DE69034040D1 (de) Rekombinanter Abkömmling des menschlichen Faktors VIII
SE9100799D0 (sv) Recombinant human factor viii derivatives
DK0711305T3 (da) Protegriner
NO971621L (no) Keratinocyttvekstfaktoranaloger
DE3883600D1 (de) Redox-aminsäuren und diese enthaltende Peptide.
DE69329899T2 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE69432427D1 (de) Tomate xyloglukan endotransglykosylase
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ATE96450T1 (de) Kleine peptide, die die bindung an t-4-rezeptoren inhibieren und als immunogene wirken.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN